Invitrogen introduces its CHO CD EfficientFeed kit for rapidly identifying the optimum feed regimen for any fed-batch CHO based cell culture
The kit will benefit scientists that want to save time by improving CHO fed-batch productivity and with developing bioreactor seed stocks.
The new CHO CD EfficientFeed kit comes with two feed supplements (one litre each of CHO CD EfficientFeed A and CHO CD EfficientFeed B) and a detailed manual.
The manual guides users through decisions relating to chemical or physical compatibility; the right feeds to use in shake flasks and bench-top bioreactors, as well as when additional support from Invitrogen PD-Direct's expert bioprocess team might be appropriate, thus ensuring quick and easy feed strategy optimisation.
CHO CD EfficientFeed A and B, based on Invitrogen's Gibco industry gold standard, chemically defined, serum free CHO media can be used to increase productivity by up to five times when compared to batch conditions.
The feeds promote either higher protein yields or cell growth kinetics, making maximum protein amounts and more cells for seeding bioreactors available in a shorter time (which could increase the number of possible bioreactor runs in a year).
Mark Stramaglia, senior product manager at Invitrogen, commented: "We realise that flexible efficiency in determining the best feeding strategy for a specific cell clone is critical for increasing productivity, which is why we are so pleased to have developed CHO CD EfficientFeed kit to address this need.
"Our experiments show the kit can be applied in shake flask and bioreactors, yet generates similar productivity increases in both and because it is simple to obtain larger, competitively priced bulk amounts (both supplements are made up from our AGT, innovative granular formulation) rapid scale-up is possible.
"This makes the CHO CD EfficientFeed kit an ideal system for forward thinking scientist that want to save time by developing a robust, scalable fed-batch process for CHO cells and could help drive down the cost of manufacturing many biopharmaceutical proteins."
